News
INZY
4.440
+2.54%
0.110
Weekly Report: what happened at INZY last week (0415-0419)?
Weekly Report · 5d ago
Weekly Report: what happened at INZY last week (0408-0412)?
Weekly Report · 04/15 09:03
Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?
Inozyme Pharma, Inc. (NASDAQ:INZY) does use debt in its business. The company has US$44.8m of debt, but also has a strong balance sheet. Its balance sheet shows that the company does not have a heavy debt load. Debt is a risky factor when a company is unable to meet its obligations with free cash flow. Inozyme Pharmaceutical has 4 warning signs we think you should know about.
Simply Wall St · 04/11 12:35
Inozyme Pharma Price Target Maintained With a $23.00/Share by Needham
Dow Jones · 04/10 10:52
Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target
Benzinga · 04/10 10:43
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Tilray Brands, Inc. (NASDAQ:TLRY) fell sharply during Tuesday's session. The company missed third-quarter estimates and said it no longer expects to generate positive free cash flow for the full fiscal year 2024. Laser Photonics Corporation shares climbed 168% to $3.82.
Benzinga · 04/09 17:12
Inozyme Pharma Is Maintained at Buy by B of A Securities
Dow Jones · 04/09 16:47
Inozyme Pharma Price Target Cut to $14.00/Share From $16.00 by B of A Securities
Dow Jones · 04/09 16:47
B of A Securities Maintains Buy on Inozyme Pharma, Lowers Price Target to $14
Benzinga · 04/09 16:38
Analysts Are Bullish on These Healthcare Stocks: Inozyme Pharma (INZY), Moderna (MRNA)
TipRanks · 04/09 11:13
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Zai Lab (ZLAB) and Idexx Laboratories (IDXX)
TipRanks · 04/09 10:20
INOZYME PHARMA, INC. <INZY.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $14 FROM $16
Reuters · 04/09 10:02
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), Inozyme Pharma (INZY) and PTC Therapeutics (PTCT)
TipRanks · 04/09 09:40
U.S. RESEARCH ROUNDUP-CME Group, Danimer Scientific, Intercontinental Exchange
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. CME Group, Danimer Scientific, Intercontinental Exchange among companies with new targets. American Eagle Outfitters, American Express among those with targets raised. Analysts also raise target prices on American Express, Alcoa and other companies.
Reuters · 04/09 07:12
Inozyme Pharma Advances with Promising INZ-701 Trial Results
TipRanks · 04/08 10:52
INOZYME PHARMA ANNOUNCES POSITIVE TOPLINE DATA FROM ONGOING PHASE 1/2 TRIALS OF INZ-701 IN ADULTS WITH ABCC6 DEFICIENCY (PXE) AND ENPP1 DEFICIENCY
Reuters · 04/08 10:30
INOZYME PHARMA INC: EXPECTS TO INITIATE A PIVOTAL TRIAL IN PEDIATRIC PATIENTS WITH ABCC6 DEFICIENCY IN Q1 2025
Reuters · 04/08 10:30
Weekly Report: what happened at INZY last week (0401-0405)?
Weekly Report · 04/08 09:03
More
Webull provides a variety of real-time INZY stock news. You can receive the latest news about Inozyme Pharma, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About INZY
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The Company is also focused on developing a novel therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-Binding Cassette in the C6 family (ABCC6) Deficiencies. The Company’s lead product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to cleave extracellular adenosine triphosphate (ATP) to generate plasma pyrophosphate (PPi) and adenosine monophosphate (AMP), which can be processed to phosphate and adenosine. Its INZ-701 is in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.